Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
The purpose of this study is to evaluate the change in patient-reported treatment
 satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care,
 using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for
 Medication (TSQM-9).
Inclusion Criteria:

 -  Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005
 revised McDonald criteria.

 -  Patients who explicitly agree to be assigned to a treatment group that may receive
 fingolimod or DMT after having been informed about their respective benefits and
 possible adverse events by the investigator.

 -  An Expanded Disability Status Scale (EDSS) score of 0-5.5 inclusive.

 -  Must have received continuous treatment with a single approved and indicated MS DMT
 for a minimum of 6 months prior to the screening visit. Patients must continue with
 this MS DMT until the randomization visit.

 -  Naïve to treatment with fingolimod.

 Exclusion Criteria:

 -  A manifestation of MS other than those defined in the inclusion criteria.

 -  A history of chronic disease of the immune system other than MS or a known
 immunodeficiency syndrome.

 -  History of malignancy of any organ system (other than localized basal cell carcinoma
 of the skin), treated or untreated, within the past 5 years, regardless of whether
 there is evidence of local recurrence or metastases.

 -  Patients with uncontrolled diabetes mellitus (HbA1c > 7%).

 -  Diagnosis of macular edema during Screening Phase.

 Other protocol-defined inclusion/exclusion criteria may apply